# Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate

> **NCT06616142** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 12 (estimated)

## Conditions studied

- Primary Aldosteronism

## Interventions

- **DRUG:** [18F]CETO tracer
- **DRUG:** Dexamethasone oral
- **PROCEDURE:** Adrenal vein sampling

## Key facts

- **NCT ID:** NCT06616142
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2026-10
- **Final completion:** 2027-05
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06616142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06616142, "Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT06616142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*